A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
← catalyst calendarNCT06695845 · readout in 134 d
Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →. With Jazz Pharmaceuticals Ireland Limited.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
200estimated
Sites
28
Countries
South Korea, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-14 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Cancer
- Gastric Cancer
- Esophageal Cancer
- Gastroesophageal Cancer
- Colorectal Cancer
- Endometrial Cancer
- Non-small Cell Lung Cancer
- Ovarian Cancer
- Urothelial Carcinoma
- Salivary Gland Cancer
- Pancreatic Cancer
- HER-2 Protein Overexpression
Intervention
- Drug: Zanidatamab — also filed as ZW25, JZP598, ZIIHERA®
Primary outcome
what the primary-completion date above is the date OFConfirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR
measured Up to 2.5 years
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed